-
Milan move to within five points of Serie A leaders Inter
-
Duplantis masterclass as Kerr and record-setter Ehammer shine
-
Rosenior urges Chelsea to 'forget the noise' after damaging loss
-
Marquez ambushed Di Giannantonio to win Brazil sprint
-
Sweden's Duplantis wins fourth world indoor pole vault title
-
Liverpool, Chelsea slip up in Champions League race
-
WHO sends first overland convoy from emergencies hub to Beirut
-
Everton rub salt in Chelsea wounds as Champions League race tightens
-
Coach Mignoni returns but Toulon crash to Stade Francais
-
Robert Mueller, ex-FBI chief who led Trump-Russia inquiry, dead at 81
-
Sinner and Pegula advance to third round at Miami Open
-
Britain's Kerr outsprints Hocker for world indoor 3,000m gold
-
Kane backs Tuchel's call to rest him from England friendly
-
NBA fines 76ers' Drummond, Magic's Suggs $25,000 each
-
Switzerland's Ehammer sets indoor heptathlon world record
-
Pogacar 'relieved' by Milan-San Remo triumph, gunning to complete Monument set
-
World Athletics decision to hand Asia two world indoors 'strategic' - Coe
-
Trump threatens to use ICE agents for airport security control
-
Kane moves closer to goals record as Bayern sink Union
-
Pogacar ends long wait for Milan-San Remo glory after edging epic
-
US says 'took out' Iran base threatening blocked Hormuz oil route
-
Di Giannantonio takes Brazil MotoGP pole ahead of Bezzecchi, Marquez
-
Welbeck scores twice to dent Liverpool's top-five hopes
-
US strikes Iran bases threatening blocked Hormuz oil route
-
Pirovano wins World Cup downhill title, Aicher puts pressure on Shiffrin
-
Doroshchuk wins Ukraine's second world indoor gold, Hodgkinson and Alfred coast
-
K-pop kings BTS stun Seoul in '2.0' comeback concert
-
French prosecutors suspect Musk encouraged deepfakes row to inflate X value
-
Mbappe 100 percent, Bellingham fit, says Real Madrid's Arbeloa
-
Iranians mark Eid as Tehran reports strike on nuclear plant
-
Kenya, Uganda open rail extension burdened by Chinese debt
-
K-pop kings BTS rock Seoul in comeback concert
-
Invincible Japan edge Australia to win Women's Asian Cup
-
Italy's Paris claims first win of season in World Cup downhill finale
-
In Finland, divers learn to explore icy polar waters
-
Dortmund extend injured captain Can's contract
-
Iranians mark Eid as Trump mulls winding down war
-
Matisse's last years cut out -- but not pasted -- at Paris expo
-
BTS fans take over central Seoul for K-pop kings' comeback
-
Star jockey McDonald becomes horse racing's most prolific Group 1 winner
-
Israel strikes Tehran, Beirut as Trump mulls 'winding down' war
-
Pistons top Warriors to clinch NBA playoff berth
-
Tickets to toothbrushes: BTS's money-making machine
-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
O.Salvador--PC